Bromocriptine unique formulation of a dopamine agonist for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 2, 2010, Pages 269-279

  Scranton, Richard ^a   Cincotta, Anthony ^a  

^a VeroScience LLC   (United States)

Author keywords

Bromocriptine; Dopamine agonist; Pharmacology; Type 2 diabetes mellitus

Indexed keywords

BROMOCRIPTINE; CYCLOSET; FATTY ACID; HEMOGLOBIN A1C; PLACEBO; PROLACTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROLACTIN BLOOD LEVEL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; BROMOCRIPTINE; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; DOPAMINE AGONISTS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; POSTPRANDIAL PERIOD; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 76749161800     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903501544     Document Type: Review

References (45)

1. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794
2. Bonora E, Kiechl S, Willeit J, et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004;53:1782-1789
3. Sahay BK, Sahay RK. Hypertension in diabetes. J Indian Med Assoc 2003;101:12,14-15
4. Haffner SM. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 2002;90:55i-61i
5. Sam S, Haffner S, Davidson MH, et al. Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes 2008;57:2022-2027
6. Kelley DE, McKolanis TM, Hegazi RA, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285:E906-16
7. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334
8. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-2898
9. D'Agostino RB Jr, Hamman RF, Karter AJ, et al. Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 2004;27:2234-2240
10. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131-1137
11. Toutouzas K, Markou V, Drakopoulou M, et al. Patients with type two diabetes mellitus: increased local inflammatory activation in culprit atheromatous plaques. Hellenic J Cardiol 2005;46:283-288 (Pubitemid 41657697)
12. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126
13. Hwang JS, Wu TL, Chou SC, et al. Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation. J Clin Lab Anal 2008;22:6-13
14. Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med 2008;25:1151-1156
15. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is . . . or is it? Lancet 1997;350(Suppl 1):SI4-9
16. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-519
17. Nakade Y, Tsukamoto K, Pappas TN, Takahashi T. Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. Brain Res 2006;1111:117-121
18. Cabou C, Campistron G, Marsollier N, et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008;57:2577-2587
19. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-1493
20. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009;11(Suppl 3):26-34
21. Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007;11:113-133
22. Cincotta A. Hypothalamic role in the insulin resistance syndrome. In: Hansen B, Shaffrir E, editors, Reistance and insulin resistance syndrome. Taylor & Francis: London; 2002. p. 271-312
23. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996;19:667-670
24. Cincotta AH, Meier AH, Cincotta M Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999;8:1683-1707
25. Meier A, Cincotta A. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev 1996;4:464-487
26. Luo S, Ezrokhi M, Trubitsyna Y, Cincotta AH. Intrahypothalamic circuitry regulating hypothalamic fuel sensing to induce insulin sensitivity or insulin resistance [abstract]. Diabetologia 2008;51(Suppl 1):S59
27. Ezrokhi M, Luo S, Cincotta J, Cincotta AH. Timed dopmaine agonist therapy induces a postprandial-selective insulin sensitivity. Diabetologia 2008;51(Suppl 1):S276
28. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 1999;69:160-166
29. Luo S, Luo J, Meier AH, Cincotta AH. Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport 1997;8:3495-3499
30. Luo S, Luo J, Cincotta AH. Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters. Neuroreport 1999;10:2073-2077
31. Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology 1998;68:1-10
32. Maurer G, Schreier E, Delaborde S, et al. Fate and disposition of bromocriptine in animals and man. I: structure elucidation of the metabolites. Eur J Drug Metab Pharmacokinet 1982;7:281-292
33. Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology 1999;70:460-465
34. Cincotta AH, Luo S, Zhang Y, et al. Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regul Integr Comp Physiol 2000;278:R435-44
35. Norvartis. Parlodel Package Insert, 2005. Available from: http://www.accessdata.fda. gov/drugsatfda-docs/label/2005/ 017962s063,064lbl.pdf [Last accessed 28 September 2009]
36. Loew DM. Effects on the central nervous system. In: Berde H, Schild H, editors, Ergot alkaloids and related compounds. Springer-Verlag: New York; 1978. p. 421-532
37. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000;23:1154-1161
38. Cincotta AH, Schiller BC, Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism 1991;40:639-644
39. Cincotta AH, Schiller BC, Landry RJ, et al. Circadian neuroendocrine role in age-related changes in body fat stores and insulin sensitivity of the male Sprague-Dawley rat. Chronobiol Int 1993;10:244-258
40. Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 1995;44:1349-1355
41. Cincotta AH, MacEachern TA, Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol 1993;264:E285-93
42. Cincotta AH, Meier AH. Prolactin permits the expression of a circadian variation in lipogenic responsiveness to insulin in hepatocytes of the golden hamster (Mesocricetus auratus). J Endocrinol 1985;106:173-176
43. Scranton RE, Gaziano JM, Rutty D. et al. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord 2007;7:3
44. VeroScience. Cycloset Package Insert, 2009. FDA approved label. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/020866lbl. pdf [Last accessed 23 September 2009]
45. Parks M. Cycloset FDA Approval Letter, 2009. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/ appletter/2009/020866s000ltr.pdf [Last accessed 23 September 2009]